MALAT1-regulated gene expression profiling in lung cancer cell lines.
Bioinformatics
LncRNA
Lung Cancer
MALAT1
NSCLC
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
04 Sep 2023
04 Sep 2023
Historique:
received:
14
06
2023
accepted:
28
08
2023
medline:
6
9
2023
pubmed:
5
9
2023
entrez:
4
9
2023
Statut:
epublish
Résumé
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and has a poor prognosis. Identifying biomarkers based on molecular mechanisms is critical for early diagnosis, timely treatment, and improved prognosis of lung cancer. MALAT1 has been reported to have overexpressed and tumor-promoting functions in NSCLC. It has been proposed as a potential biomarker for the diagnosis and prognosis of cancer. Therefore, this study was conducted to profile the changes in gene expression according to the regulation of expression of MALAT1 in NSCLC cell lines and to investigate the correlation through bioinformatic analysis of differentially expressed genes (DEGs). MALAT1 expression levels were measured using RT-qPCR. The biological functions of MALAT1 in NSCLC were analyzed by cell counting, colony forming, wound-healing, and Transwell invasion assays. In addition, gene expression profiling in response to the knockdown of MALAT1 was analyzed by transcriptome sequencing, and differentially expressed genes regulated by MALAT1 were performed by GO and KEGG pathway enrichment analyses. Bioinformatic databases were used for gene expression analysis and overall survival analysis. Comparative analysis versus MALAT1 expression in MRC5 cells (a normal lung cell line) and the three NSCLC cell lines showed that MALAT1 expression was significantly higher in the NSCLC cells. MALAT1 knockdown decreased cell survival, proliferation, migration, and invasion in all three NSCLC cell lines. RNA-seq analysis of DEGs in NSCLC cells showed 198 DEGs were upregulated and 266 DEGs downregulated by MALAT1 knockdown in all three NSCLC cell lines. Survival analysis on these common DEGs performed using the OncoLnc database resulted in the selection of five DEGs, phosphoglycerate mutase 1 (PGAM1), phosphoglycerate mutase 4 (PGAM4), nucleolar protein 6 (NOL6), nucleosome assembly protein 1 like 5 (NAP1L5), and sestrin1 (SESN1). The gene expression levels of these selected DEGs were proved to gene expression analysis using the TNMplot database. MALAT1 might function as an oncogene that enhances NSCLC cell survival, proliferation, colony formation, and invasion. RNA-seq and bioinformatic analyses resulted in the selection of five DEGs, PGAM1, PGAM4, NOL6, NAP1L5, and SESN1, which were found to be closely related to patient survival and tumorigenesis. We believe that further investigation of these five DEGs will provide valuable information on the oncogenic role of MALAT1 in NSCLC.
Sections du résumé
BACKGROUND
BACKGROUND
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and has a poor prognosis. Identifying biomarkers based on molecular mechanisms is critical for early diagnosis, timely treatment, and improved prognosis of lung cancer. MALAT1 has been reported to have overexpressed and tumor-promoting functions in NSCLC. It has been proposed as a potential biomarker for the diagnosis and prognosis of cancer. Therefore, this study was conducted to profile the changes in gene expression according to the regulation of expression of MALAT1 in NSCLC cell lines and to investigate the correlation through bioinformatic analysis of differentially expressed genes (DEGs).
METHODS
METHODS
MALAT1 expression levels were measured using RT-qPCR. The biological functions of MALAT1 in NSCLC were analyzed by cell counting, colony forming, wound-healing, and Transwell invasion assays. In addition, gene expression profiling in response to the knockdown of MALAT1 was analyzed by transcriptome sequencing, and differentially expressed genes regulated by MALAT1 were performed by GO and KEGG pathway enrichment analyses. Bioinformatic databases were used for gene expression analysis and overall survival analysis.
RESULTS
RESULTS
Comparative analysis versus MALAT1 expression in MRC5 cells (a normal lung cell line) and the three NSCLC cell lines showed that MALAT1 expression was significantly higher in the NSCLC cells. MALAT1 knockdown decreased cell survival, proliferation, migration, and invasion in all three NSCLC cell lines. RNA-seq analysis of DEGs in NSCLC cells showed 198 DEGs were upregulated and 266 DEGs downregulated by MALAT1 knockdown in all three NSCLC cell lines. Survival analysis on these common DEGs performed using the OncoLnc database resulted in the selection of five DEGs, phosphoglycerate mutase 1 (PGAM1), phosphoglycerate mutase 4 (PGAM4), nucleolar protein 6 (NOL6), nucleosome assembly protein 1 like 5 (NAP1L5), and sestrin1 (SESN1). The gene expression levels of these selected DEGs were proved to gene expression analysis using the TNMplot database.
CONCLUSION
CONCLUSIONS
MALAT1 might function as an oncogene that enhances NSCLC cell survival, proliferation, colony formation, and invasion. RNA-seq and bioinformatic analyses resulted in the selection of five DEGs, PGAM1, PGAM4, NOL6, NAP1L5, and SESN1, which were found to be closely related to patient survival and tumorigenesis. We believe that further investigation of these five DEGs will provide valuable information on the oncogenic role of MALAT1 in NSCLC.
Identifiants
pubmed: 37667226
doi: 10.1186/s12885-023-11347-7
pii: 10.1186/s12885-023-11347-7
pmc: PMC10476395
doi:
Substances chimiques
Phosphoglycerate Mutase
EC 5.4.2.11
RNA, Long Noncoding
0
MALAT1 long non-coding RNA, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
818Subventions
Organisme : National Research Foundation of Korea
ID : 2022R1A6A3A13072277
Organisme : National Research Foundation of Korea
ID : 2019R1C1C1009423
Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
pubmed: 30207593
doi: 10.3322/caac.21492
Hoffman PC, Mauer AM, Vokes EE. Lung cancer. Lancet. 2000;355(9202):479–85.
pubmed: 10841143
doi: 10.1016/S0140-6736(00)82038-3
Shriwash N, Singh P, Arora S, Ali SM, Ali S, Dohare R. Identification of differentially expressed genes in small and non-small cell lung cancer based on meta-analysis of mRNA. Heliyon. 2019;5(6):e01707.
pubmed: 31338439
pmcid: 6580189
doi: 10.1016/j.heliyon.2019.e01707
Slawinski G, Wrona A, Dabrowska-Kugacka A, Raczak G, Lewicka E. Immune Checkpoint inhibitors and Cardiac Toxicity in Patients treated for Non-Small Lung Cancer: a review. Int J Mol Sci 2020, 21(19).
Li P, Chen X, Zhou S, Xia X, Wang E, Han R, Zeng D, Fei G, Wang R. High expression of DEPDC1B predicts poor prognosis in Lung Adenocarcinoma. J Inflamm Res. 2022;15:4171–84.
pubmed: 35912402
pmcid: 9332445
doi: 10.2147/JIR.S369219
Sanchez Calle A, Kawamura Y, Yamamoto Y, Takeshita F, Ochiya T. Emerging roles of long non-coding RNA in cancer. Cancer Sci. 2018;109(7):2093–100.
pubmed: 29774630
pmcid: 6029823
doi: 10.1111/cas.13642
Qian Y, Shi L, Luo Z. Long non-coding RNAs in Cancer: implications for diagnosis, prognosis, and Therapy. Front Med (Lausanne). 2020;7:612393.
pubmed: 33330574
doi: 10.3389/fmed.2020.612393
Do H, Kim W. Roles of oncogenic long non-coding RNAs in Cancer Development. Genomics Inf. 2018;16(4):e18.
doi: 10.5808/GI.2018.16.4.e18
Jin H, Du W, Huang W, Yan J, Tang Q, Chen Y, Zou Z. lncRNA and breast cancer: progress from identifying mechanisms to challenges and opportunities of clinical treatment. Mol Ther Nucleic Acids. 2021;25:613–37.
pubmed: 34589282
pmcid: 8463317
doi: 10.1016/j.omtn.2021.08.005
Chae Y, Roh J, Kim W. The Roles played by long non-coding RNAs in Glioma Resistance. Int J Mol Sci 2021, 22(13).
Seo D, Kim D, Kim W. Long non-coding RNA linc00152 acting as a promising oncogene in cancer progression. Genomics Inf. 2019;17(4):e36.
doi: 10.5808/GI.2019.17.4.e36
Liu XH, Sun M, Nie FQ, Ge YB, Zhang EB, Yin DD, Kong R, Xia R, Lu KH, Li JH, et al. Lnc RNA HOTAIR functions as a competing endogenous RNA to regulate HER2 expression by sponging mir-331-3p in gastric cancer. Mol Cancer. 2014;13:92.
pubmed: 24775712
pmcid: 4021402
doi: 10.1186/1476-4598-13-92
Roh J, Im M, Kang J, Youn B, Kim W. Long non-coding RNA in glioma: novel genetic players in temozolomide resistance. Anim Cells Syst (Seoul). 2023;27(1):19–28.
pubmed: 36819921
doi: 10.1080/19768354.2023.2175497
Arun G, Aggarwal D, Spector DL. MALAT1 long non-coding RNA: functional implications. Noncoding RNA 2020, 6(2).
Ye D, Deng Y, Shen Z. The role and mechanism of MALAT1 long non-coding RNA in the diagnosis and treatment of Head and Neck squamous cell carcinoma. Onco Targets Ther. 2021;14:4127–36.
pubmed: 34267526
pmcid: 8275198
doi: 10.2147/OTT.S317234
Li ZX, Zhu QN, Zhang HB, Hu Y, Wang G, Zhu YS. MALAT1: a potential biomarker in cancer. Cancer Manag Res. 2018;10:6757–68.
pubmed: 30584369
pmcid: 6289210
doi: 10.2147/CMAR.S169406
Yu W, Ding J, He M, Chen Y, Wang R, Han Z, Xing EZ, Zhang C, Yeh S. Estrogen receptor beta promotes the vasculogenic mimicry (VM) and cell invasion via altering the lncRNA-MALAT1/miR-145-5p/NEDD9 signals in lung cancer. Oncogene. 2019;38(8):1225–38.
pubmed: 30250297
doi: 10.1038/s41388-018-0463-1
Duan G, Zhang C, Xu C, Xu C, Zhang L, Zhang Y. Knockdown of MALAT1 inhibits osteosarcoma progression via regulating the miR–34a/cyclin D1 axis. Int J Oncol. 2019;54(1):17–28.
pubmed: 30365098
Chang J, Xu W, Du X, Hou J. MALAT1 silencing suppresses prostate cancer progression by upregulating miR-1 and downregulating KRAS. Onco Targets Ther. 2018;11:3461–73.
pubmed: 29942138
pmcid: 6007192
doi: 10.2147/OTT.S164131
Seo D, Kim D, Chae Y, Kim W. The ceRNA network of lncRNA and miRNA in lung cancer. Genomics Inf. 2020;18(4):e36.
doi: 10.5808/GI.2020.18.4.e36
Rosell R, Bivona TG, Karachaliou N. Genetics and biomarkers in personalisation of lung cancer treatment. Lancet. 2013;382(9893):720–31.
pubmed: 23972815
doi: 10.1016/S0140-6736(13)61715-8
Cui Y, Li G, Zhang X, Dai F, Zhang R. Increased MALAT1 expression contributes to cisplatin resistance in non-small cell lung cancer. Oncol Lett. 2018;16(4):4821–8.
pubmed: 30250547
pmcid: 6144744
Yang Q, Chen W, Xu Y, Lv X, Zhang M, Jiang H. Polyphyllin I modulates MALAT1/STAT3 signaling to induce apoptosis in gefitinib-resistant non-small cell lung cancer. Toxicol Appl Pharmacol. 2018;356:1–7.
pubmed: 30076870
doi: 10.1016/j.taap.2018.07.031
Hao L, Wu W, Xu Y, Chen Y, Meng C, Yun J, Wang X. LncRNA-MALAT1: a key participant in the occurrence and development of Cancer. Molecules 2023, 28(5).
Brown JA, Valenstein ML, Yario TA, Tycowski KT, Steitz JA. Formation of triple-helical structures by the 3’-end sequences of MALAT1 and MENβ noncoding RNAs. Proc Natl Acad Sci U S A. 2012;109(47):19202–7.
pubmed: 23129630
pmcid: 3511071
doi: 10.1073/pnas.1217338109
Kang J, Kim W, Lee S, Kwon D, Chun J, Son B, Kim E, Lee JM, Youn H, Youn B. TFAP2C promotes lung tumorigenesis and aggressiveness through miR-183- and miR-33a-mediated cell cycle regulation. Oncogene. 2017;36(11):1585–96.
pubmed: 27593936
doi: 10.1038/onc.2016.328
Kang J, Kim W, Seo H, Kim E, Son B, Lee S, Park G, Jo S, Moon C, Youn H, et al. Radiation-induced overexpression of transthyretin inhibits retinol-mediated hippocampal neurogenesis. Sci Rep. 2018;8(1):8394.
pubmed: 29849106
pmcid: 5976673
doi: 10.1038/s41598-018-26762-1
Do H, Kim D, Kang J, Son B, Seo D, Youn H, Youn B, Kim W. TFAP2C increases cell proliferation by downregulating GADD45B and PMAIP1 in non-small cell lung cancer cells. Biol Res. 2019;52(1):35.
pubmed: 31296259
pmcid: 6625030
doi: 10.1186/s40659-019-0244-5
Kim W, Youn H, Lee S, Kim E, Kim D, Sub Lee J, Lee JM, Youn B. RNF138-mediated ubiquitination of rpS3 is required for resistance of glioblastoma cells to radiation-induced apoptosis. Exp Mol Med. 2018;50(1):e434.
pubmed: 29371697
pmcid: 5799804
doi: 10.1038/emm.2017.247
Kim E, Kim W, Lee S, Chun J, Kang J, Park G, Han I, Yang HJ, Youn H, Youn B. TRAF4 promotes lung cancer aggressiveness by modulating tumor microenvironment in normal fibroblasts. Sci Rep. 2017;7(1):8923.
pubmed: 28827764
pmcid: 5566719
doi: 10.1038/s41598-017-09447-z
Ni T, Wang H, Li D, Tao L, Lv M, Jin F, Wang W, Feng J, Qian Y, Sunagawa M, et al. Huachansu Capsule inhibits the proliferation of human gastric cancer cells via Akt/mTOR pathway. Biomed Pharmacother. 2019;118:109241.
pubmed: 31351435
doi: 10.1016/j.biopha.2019.109241
Seo D, Roh J, Chae Y, Kim W. Gene expression profiling after LINC00472 overexpression in an NSCLC cell line1. Cancer Biomark. 2021;32(2):175–88.
pubmed: 34397405
doi: 10.3233/CBM-210242
Kim D, Langmead B, Salzberg SL. HISAT: a fast spliced aligner with low memory requirements. Nat Methods. 2015;12(4):357–60.
pubmed: 25751142
pmcid: 4655817
doi: 10.1038/nmeth.3317
Pertea M, Kim D, Pertea GM, Leek JT, Salzberg SL. Transcript-level expression analysis of RNA-seq experiments with HISAT, StringTie and Ballgown. Nat Protoc. 2016;11(9):1650–67.
pubmed: 27560171
pmcid: 5032908
doi: 10.1038/nprot.2016.095
Pertea M, Pertea GM, Antonescu CM, Chang TC, Mendell JT, Salzberg SL. StringTie enables improved reconstruction of a transcriptome from RNA-seq reads. Nat Biotechnol. 2015;33(3):290–5.
pubmed: 25690850
pmcid: 4643835
doi: 10.1038/nbt.3122
Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000;25(1):25–9.
pubmed: 10802651
pmcid: 3037419
doi: 10.1038/75556
Aleksander SA, Balhoff J, Carbon S, Cherry JM, Drabkin HJ, Ebert D, Feuermann M, Gaudet P, Harris NL, Hill DP et al. The Gene Ontology knowledgebase in 2023. Genetics 2023, 224(1).
Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28(1):27–30.
pubmed: 10592173
pmcid: 102409
doi: 10.1093/nar/28.1.27
Kanehisa M. Toward understanding the origin and evolution of cellular organisms. Protein Sci. 2019;28(11):1947–51.
pubmed: 31441146
pmcid: 6798127
doi: 10.1002/pro.3715
Kanehisa M, Furumichi M, Sato Y, Kawashima M, Ishiguro-Watanabe M. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 2023;51(D1):D587–d592.
pubmed: 36300620
doi: 10.1093/nar/gkac963
Sherman BT, Hao M, Qiu J, Jiao X, Baseler MW, Lane HC, Imamichi T, Chang W. DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update). Nucleic Acids Res. 2022;50(W1):W216–w221.
pubmed: 35325185
pmcid: 9252805
doi: 10.1093/nar/gkac194
Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44–57.
pubmed: 19131956
doi: 10.1038/nprot.2008.211
Anaya J. OncoLnc: linking TCGA survival data to mRNAs, miRNAs, and lncRNAs. PeerJ Comput Sci 2016, 2.
Mo CH, Gao L, Zhu XF, Wei KL, Zeng JJ, Chen G, Feng ZB. The clinicopathological significance of UBE2C in breast cancer: a study based on immunohistochemistry, microarray and RNA-sequencing data. Cancer Cell Int. 2017;17:83.
pubmed: 29021715
pmcid: 5613379
doi: 10.1186/s12935-017-0455-1
Bartha A, Gyorffy B. TNMplot.com: a web Tool for the comparison of Gene expression in normal, Tumor and metastatic tissues. Int J Mol Sci 2021, 22(5).
Zhang Y, Yang J, Wang X, Li X. GNG7 and ADCY1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma through bioinformatic-based analyses. Sci Rep. 2021;11(1):20441.
pubmed: 34650124
pmcid: 8516928
doi: 10.1038/s41598-021-99544-x
Wang H, Yang L, Liu M, Luo J. Protein post-translational modifications in the regulation of cancer hallmarks. Cancer Gene Ther. 2023;30(4):529–47.
pubmed: 35393571
doi: 10.1038/s41417-022-00464-3
Hynes NE, MacDonald G. ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol. 2009;21(2):177–84.
pubmed: 19208461
doi: 10.1016/j.ceb.2008.12.010
Yan M, Sun L, Li J, Yu H, Lin H, Yu T, Zhao F, Zhu M, Liu L, Geng Q, et al. RNA-binding protein KHSRP promotes tumor growth and metastasis in non-small cell lung cancer. J Exp Clin Cancer Res. 2019;38(1):478.
pubmed: 31775888
pmcid: 6882349
doi: 10.1186/s13046-019-1479-2
Boroughs LK, DeBerardinis RJ. Metabolic pathways promoting cancer cell survival and growth. Nat Cell Biol. 2015;17(4):351–9.
pubmed: 25774832
pmcid: 4939711
doi: 10.1038/ncb3124
Roh J, Im M, Chae Y, Kang J, Kim W. The involvement of long non-coding RNAs in glutamine-metabolic reprogramming and therapeutic resistance in Cancer. Int J Mol Sci 2022, 23(23).
Fukushi A, Kim HD, Chang YC, Kim CH. Revisited metabolic control and reprogramming cancers by means of the Warburg Effect in Tumor cells. Int J Mol Sci 2022, 23(17).
Rong F, Liu L, Zou C, Zeng J, Xu Y. MALAT1 promotes cell tumorigenicity through regulating miR-515-5p/EEF2 Axis in Non-Small Cell Lung Cancer. Cancer Manag Res. 2020;12:7691–701.
pubmed: 32943920
pmcid: 7468487
doi: 10.2147/CMAR.S242425
Chen B, Yang L, Zhang R, Gan Y, Zhang W, Liu D, Chen H, Tang H. Hyperphosphorylation of RPS6KB1, rather than overexpression, predicts worse prognosis in non-small cell lung cancer patients. PLoS ONE. 2017;12(8):e0182891.
pubmed: 28792981
pmcid: 5549961
doi: 10.1371/journal.pone.0182891
Li S, Mei Z, Hu HB, Zhang X. The lncRNA MALAT1 contributes to non-small cell lung cancer development via modulating miR-124/STAT3 axis. J Cell Physiol. 2018;233(9):6679–88.
pubmed: 29215698
doi: 10.1002/jcp.26325
Okudela K, Mitsui H, Suzuki T, Woo T, Tateishi Y, Umeda S, Saito Y, Tajiri M, Masuda M, Ohashi K. Expression of HDAC9 in lung cancer–potential role in lung carcinogenesis. Int J Clin Exp Pathol. 2014;7(1):213–20.
pubmed: 24427341
Iwasaki Y, Sunaga N, Tomizawa Y, Imai H, Iijima H, Yanagitani N, Horiguchi K, Yamada M, Mori M. Epigenetic inactivation of the thyroid hormone receptor beta1 gene at 3p24.2 in lung cancer. Ann Surg Oncol. 2010;17(8):2222–8.
pubmed: 20155399
doi: 10.1245/s10434-010-0956-9
Lou Z, Lin W, Zhao H, Jiao X, Wang C, Zhao H, Liu L, Liu Y, Xie Q, Huang X, et al. Alkaline phosphatase downregulation promotes lung adenocarcinoma metastasis via the c-Myc/RhoA axis. Cancer Cell Int. 2021;21(1):217.
pubmed: 33858415
pmcid: 8050923
doi: 10.1186/s12935-021-01919-7
Zhang X, Zhang R, Liu P, Zhang R, Ning J, Ye Y, Yu W, Yu J. ATP8B1 Knockdown activated the Choline Metabolism Pathway and Induced High-Level Intracellular REDOX Homeostasis in Lung squamous cell carcinoma. Cancers (Basel) 2022, 14(3).
Appert-Collin A, Hubert P, Cremel G, Bennasroune A. Role of ErbB receptors in Cancer Cell Migration and Invasion. Front Pharmacol. 2015;6:283.
pubmed: 26635612
pmcid: 4657385
doi: 10.3389/fphar.2015.00283
Ogretmen B. Sphingolipid metabolism in cancer signalling and therapy. Nat Rev Cancer. 2018;18(1):33–50.
pubmed: 29147025
doi: 10.1038/nrc.2017.96
Burston HE, Kent OA, Communal L, Udaskin ML, Sun RX, Brown KR, Jung E, Francis KE, La Rose J, Lowitz J et al. Inhibition of relaxin autocrine signaling confers therapeutic vulnerability in ovarian cancer. J Clin Invest 2021, 131(7).
Brannan JM, Sen B, Saigal B, Prudkin L, Behrens C, Solis L, Dong W, Bekele BN, Wistuba I, Johnson FM. EphA2 in the early pathogenesis and progression of non-small cell lung cancer. Cancer Prev Res (Phila). 2009;2(12):1039–49.
pubmed: 19934338
doi: 10.1158/1940-6207.CAPR-09-0212
Zhang T, Liu C, Yu Y, Geng J, Meng Q, Xu S, Zhou F, Chen Y, Jin S, Shen J, et al. TBL1XR1 is involved in c-Met-mediated tumorigenesis of human nonsmall cell lung cancer. Cancer Gene Ther. 2020;27(3–4):136–46.
pubmed: 31243347
doi: 10.1038/s41417-019-0111-0
Tong Y, Chen X, Feng Z, Xu C, Li Y. Keratin 80 promotes Migration and Invasion of Non-Small Cell Lung Cancer cells by regulating the TGF-beta/SMAD pathway. Evid Based Complement Alternat Med. 2022;2022:2630351.
pubmed: 36248424
pmcid: 9553464
doi: 10.1155/2022/2630351
Melese ES, Franks E, Cederberg RA, Harbourne BT, Shi R, Wadsworth BJ, Collier JL, Halvorsen EC, Johnson F, Luu J, et al. CCL5 production in lung cancer cells leads to an altered immune microenvironment and promotes tumor development. Oncoimmunology. 2022;11(1):2010905.
pubmed: 35481284
doi: 10.1080/2162402X.2021.2010905
Wang X, Liu R, Zhu W, Chu H, Yu H, Wei P, Wu X, Zhu H, Gao H, Liang J, et al. UDP-glucose accelerates SNAI1 mRNA decay and impairs lung cancer metastasis. Nature. 2019;571(7763):127–31.
pubmed: 31243371
doi: 10.1038/s41586-019-1340-y
Xing Y, Meng Q, Chen X, Zhao Y, Liu W, Hu J, Xue F, Wang X, Cai L. TRIM44 promotes proliferation and metastasis in non–small cell lung cancer via mTOR signaling pathway. Oncotarget. 2016;7(21):30479–91.
pubmed: 27058415
pmcid: 5058694
doi: 10.18632/oncotarget.8586
Lin X, Tan S, Fu L, Dong Q. BCAT1 overexpression promotes proliferation, Invasion, and wnt signaling in Non-Small Cell Lung Cancers. Onco Targets Ther. 2020;13:3583–94.
pubmed: 32425554
pmcid: 7196801
doi: 10.2147/OTT.S237306
Li F, Yang H, Kong T, Chen S, Li P, Chen L, Cheng J, Cui G, Zhang G. PGAM1, regulated by miR-3614-5p, functions as an oncogene by activating transforming growth factor-beta (TGF-beta) signaling in the progression of non-small cell lung carcinoma. Cell Death Dis. 2020;11(8):710.
pubmed: 32855383
pmcid: 7453026
doi: 10.1038/s41419-020-02900-4
Jin Q, Pan H, Wang B, Wang J, Liu T, Yu X, Jia C, Fang X, Peng Y, Ma X. The PGAM4 gene in non-obstructive azoospermia. Syst Biol Reprod Med. 2013;59(4):179–83.
pubmed: 23631659
doi: 10.3109/19396368.2013.783887
Dierick HA, Mercer JF, Glover TW. A phosphoglycerate mutase brain isoform (PGAM 1) pseudogene is localized within the human Menkes disease gene (ATP7 A). Gene. 1997;198(1–2):37–41.
pubmed: 9370262
doi: 10.1016/S0378-1119(97)00289-8
Okuda H, Tsujimura A, Irie S, Yamamoto K, Fukuhara S, Matsuoka Y, Takao T, Miyagawa Y, Nonomura N, Wada M, et al. A single nucleotide polymorphism within the novel sex-linked testis-specific retrotransposed PGAM4 gene influences human male fertility. PLoS ONE. 2012;7(5):e35195.
pubmed: 22590500
pmcid: 3348931
doi: 10.1371/journal.pone.0035195
Lu B, Nie XH, Yin R, Ding P, Su ZZ, Qiu S, Qian YF. PGAM4 silencing inhibited glycolysis and chemoresistance to temozolomide in glioma cells. Cell Biol Int. 2023;47(4):776–86.
pubmed: 36576012
doi: 10.1002/cbin.11983
He L, Qian X, Ge P, Fan D, Ma X, Wu Q, Sun J, Yang L, Shen J, Xu L. NOL6 regulates the proliferation and apoptosis of gastric Cancer cells via regulating TP53I3, CDK4 and MCM7 expression. Front Oncol. 2022;12:708081.
pubmed: 35494047
pmcid: 9039204
doi: 10.3389/fonc.2022.708081
Liang J, Sun W, Song H, Wang C, Li Q, Li C, Wei D, Zhao Y, Li C, Zhang H. NOL6 promotes the proliferation and migration of endometrial cancer cells by regulating TWIST1 expression. Epigenomics. 2021;13(19):1571–85.
pubmed: 34607487
doi: 10.2217/epi-2021-0218
Zhao R, Ge Y, Gong Y, Li B, Xiao B, Zuo S. NAP1L5 targeting combined with MYH9 inhibit HCC progression through PI3K/AKT/mTOR signaling pathway. Aging. 2022;14(22):9000–19.
pubmed: 36374212
pmcid: 9740361
doi: 10.18632/aging.204377
Ding B, Haidurov A, Chawla A, Parmigiani A, van de Kamp G, Dalina A, Yuan F, Lee JH, Chumakov PM, Grossman SR, et al. p53-inducible SESTRINs might play opposite roles in the regulation of early and late stages of lung carcinogenesis. Oncotarget. 2019;10(65):6997–7009.
pubmed: 31857853
pmcid: 6916756
doi: 10.18632/oncotarget.27367